IFNGR1 and neoplasm: Optineurin maintains pathway integrity by blocking IFNGR1 palmitoylation (Cys122)-dependent lysosomal sorting via AP3D1. Targeting IFNGR1 palmitoylation stabilizes IFNGR1, enhances tumor immunity, and sensitizes to checkpoint therapy (Figure 4A) (23).